TB Alliance

TB Alliance Stakeholders Association: Call for community representative

The Global Alliance for TB Drug Development (TB Alliance) is seeking applications for the community representative to its Stakeholders Association.

Read More →

Penn State, TB Alliance, and GSK partner to discover new treatments for TB

UNIVERSITY PARK, Pa., June 27, 2016 -- A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).

Read More →

TB Alliance and Takeda announce advancement of joint program investigating promising compounds for novel TB therapies

NEW YORK AND OSAKA (June 21, 2016) — TB Alliance and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan; “Takeda”) announced that they have entered into an agreement that further explores hits generated from a high-throughput screening program conducted to find novel compounds to improve treatment of tuberculosis (TB). The joint research program is funded through the Global Health Innovative Technology (GHIT) Fund, established for the purpose of promoting research and development of pharmaceutical products, vaccines and diagnostics needed for communicable diseases.

Read More →

TB Alliance and the Medicines Patent Pool sign Memorandum of Understanding to improve access to TB medicines in resource-limited nations

NEW YORK AND GENEVA (April 20, 2016) – TB Alliance and the Medicines Patent Pool (MPP) today announced a Memorandum of Understanding outlining a multi-pronged collaboration to encourage the development of new tuberculosis (TB) regimens and ensure their availability in low-and middle-income countries. The two organisations will work together on a range of initiatives, with a focus on public health-oriented licensing strategies and the sharing of intellectual property to spur research and development of affordable new TB treatments.

Read More →

Phase 1 clinical trial of TB drug candidate TBA-354 discontinued

More investment is needed to expand the portfolio of new TB drug candidates.

Read More →

Phase 1 TBA-354 placed on clinical hold

January 4, 2016 - TB Alliance announced today that it has voluntarily halted further dosing of TBA-354 in the ongoing Multiple Ascending Dose (MAD) Phase 1 study. This action has prompted the United States Food and Drug Administration (FDA) to place the organization’s Investigational New Drug (IND) submission for TBA-354 on clinical hold. TBA-354, which had entered Phase 1 testing in early 2015, is from the nitroimidazole class of chemicals.

Read More →

Sign a petition: Tell world leaders to end childhood tuberculosis

The petition will be open for signatures until World TB Day, March 2016, when it will be presented to world leaders.

Read More →

TB Alliance and partners announce world’s first availability of appropriate, child-friendly TB medicines in correct doses

Medication simplifies and improves treatment for 1 million children with TB; Medicines come in dispersible fixed-dose combinations at the correct dosages, tablets no longer need to be cut or crushed; These products can improve adherence and child survival from TB.

Read More →

TB Alliance launches “Nix-TB” clinical trial to test new XDR-TB treatment

First clinical trial to test a new all-oral regimen for extensively drug-resistant TB; Nix-TB is a critical step in the development of a universal treatment for all types of TB.

Read More →

Host for new TB clinical trial data-sharing platform selected

TUCSON, Ariz., April 29, 2015 — The non-profit Critical Path Institute has been selected to host a new tuberculosis (TB) clinical trial data sharing platform. The initiative will start by creating a common database from three Phase III clinical trials earlier supported by the Special Programme for Research and Training in Tropical Diseases (TDR), the TB Alliance and St. George’s, University of London.

Read More →

Page 2 of 6 · Total posts: 10

←First 1 2 3 Last→